Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.3.2-01 | Award Amount: 13.29M | Year: 2012
The PharmaSea project focuses on obstacles in marine biodiscovery research, development and commercialization and brings together a broad interdisciplinary team of academic and industry researchers and specialists to address and overcome these. The partners are ideally placed to demonstrate how to widen the bottlenecks and increase the flow of ideas and products derived from the marine microbiome towards a greater number of successes in a larger number of application areas. Despite the tremendous potential of marine biodiscovery, exploitation, particularly at a commercial scale, has been hampered by a number of constraints. These relate to access (physical and legal), genetics of the organisms, compound isolation, structure elucidation, early reliable validation of biological activity and best mechanisms of flow-through into exploitation. PharmaSea will solve these chronic bottlenecks by developing essential actions beyond the state of the art and linking them with best practice and appropriate pragmatic approaches. The robust pipeline structure established within PharmaSea will process a wide genetic basis including marine microbial strain collections held by partners and new strain collections from extreme environments (deep, cold and hot vent habitats) to produce new products with desirable characteristics for development by the SME partners in three accessible market sectors, health (infection, inflammation, CNS diseases), personal care and nutrition. The global aim of PharmaSea is to produce two compounds at larger scale and advance them to pre-clinical evaluation. To address relevant challenges in marine biodiscovery related to policy and legal issues, PharmaSea will bring together practitioners, legal experts, policy advisors/makers and other stakeholders, focusing on the feasibility of harmonising, aligning and complementing current legal frameworks with recommendations and ready to use solutions tailored to marine biodiscovery.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: KBBE-2007-2-3-03 | Award Amount: 4.10M | Year: 2008
Functional foods provide a buoyant growth sector and the use of carotenoids is the most dynamic not only as colorants but as food additives. One issue with these products is their instability both on the shelf and upon digestion. Recently, gastric-stable bacterial-derived carotenoid preparations have been discovered by members of this consortium and these 2nd generation carotenoid preparations, and the bacteria that produce them will be studied. Existing prototypes will be developed as potential food additives but an extensive screen for new 2nd generation prototypes will also be made from marine environments. The consortium includes microbiologists, biochemists and food bio-technologists and will determine the identity of new carotenoid preparations and the bacteria that produce them. The nutritional value of these bacteria will be assessed and a risk-benefit assessment made using modern metabolomic technologies as well as traditional toxicology in order to designate the prototypes as QPS (ie, qualified presumption of safety). Bioprocessing of these bacterial carotenoid preparations will eliminate traditional chemical synthesis and the use of organic solvents. Also the delivery system will utilise a synergistic biological matrix making it a sustainable source. The use of these bacteria as colour-nutritional additives will be assessed by process optimisations, colour and texture analysis. The consortium includes 9 partners, including one ICPC and one associated country. Two IND partners, one an SME, will work together to exploit prototypes as additives, colourants and as functional foods. This will include patenting, licensing and the opening of new markets. Both IND partners are looking for new markets in the food additive/functional food sector and this project will enable them to identify new markets. The project will directly impact the food industry by developing new, natural as well as novel food additives and ingredients that can replace synthetic ones.
Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.3.2-02 | Award Amount: 11.97M | Year: 2012
Marine microorganisms form an almost untapped resource of biotechnological potential. However, its use is hindered by the low success rate of isolation of novel microorganisms and often by poor growth efficiency. Hence, the vast majority of marine microorganisms has not been cultivated and is often considered as unculturable. MaCuMBA aims at improving the isolation rate and growth efficiency of marine microorganisms from conventional and extreme habitats, by applying innovative methods, and the use of automated high throughput procedures. The approaches include the co-cultivation of interdependent microorganisms, as well as gradient cultures and other methods mimicking the natural environment, and the exploitation of cell-to-cell communication. Signaling molecules produced by microorganisms may be necessary for stimulating growth of the same or other species, or may prevent their growth. Signaling molecules also represent an interesting and marketable product. MaCuMBA will make use of high throughput platforms such Cocagne, using gel micro-droplet technology, or MicroDish in which many thousands of cultures are grown simultaneously. Various single-cell isolation methods, such as optical tweezers, will aid the isolation of specific target cells. Isolated microorganisms as well as their genomes will be screened for a wide range of bioactive products and other properties of biotechnological interest, such as genetic transformability. Growth efficiency and expression of silent genes of selected strains will be increased also by using the clues obtained from genomic information. MaCuMBA is targeted to SMEs and industry and they make a significant part of the consortium, ensuring that the project focuses on the interests of these partners. Moreover, MaCuMBA has adopted a comprehensive and professional exploitation, dissemination, implementation, and education strategy, ensuring that MaCuMBAs results and products will be directed to end-users and stakeholders.
Lallemand U.K. Ltd and Aquapharm Bio Discovery Ltd | Date: 2012-02-15
Chemical preparations and chemical products for use in industry; chemical preparations and chemical products for use in toiletries, cosmetics and skin care preparations; raw materials and ingredients for use in toiletries, cosmetics and skin care preparations; chemical preparations, products and substances for use as ingredients for foodstuffs; chemical preparations, products and substances for use as ingredients for beverages; chemical preparations, products and substances for use as ingredients or additives for nutraceuticals. Non-medicated toilet preparations; cosmetics; skin care preparations; toiletries; bath and shower preparations; hair care preparations; shampoos; perfumery; essential oils; soaps; deodorants for personal use; ingredients for use in toiletries, cosmetics, skin care preparations, bath and shower preparations, hair care preparations and shampoos; products containing active ingredients for toilet and cosmetic purposes. Pharmaceutical preparations and substances; nutraceutical preparations and substances; dietetic substances adapted for medical use; preparations containing or based on vitamins, trace elements and/or minerals for dietetic purposes or as nutritional supplements; food supplements for medical purposes; nutritional supplements for medical purposes; health food supplements; mineral food supplements; vitamins and minerals; vitamin preparations in the nature of food supplements; mineral preparations in the nature of food supplements; vitamin drinks adapted for medical purposes; mineral drinks adapted for medical purposes; pharmaceutical preparations to be used as additives to foodstuffs; pharmaceutical preparations to be used as additives to beverages; medicated lotions; medicated skin care preparations; medicated bath and shower preparations; medicated preparations for the care of the scalp.
Novak H.R.,University of Exeter |
Sayer C.,University of Exeter |
Isupov M.N.,University of Exeter |
Gotz D.,Aquapharm Biodiscovery Ltd. |
And 2 more authors.
FEBS Letters | Year: 2014
A putative haloalkane dehalogenase has been identified in a marine Rhodobacteraceae and subsequently cloned and over-expressed in Escherichia coli. The enzyme has highest activity towards the substrates 1,6-dichlorohexane, 1-bromooctane, 1,3-dibromopropane and 1-bromohexane. The crystal structures of the enzyme in the native and product bound forms reveal a large hydrophobic active site cavity. A deeper substrate binding pocket defines the enzyme preference towards substrates with longer carbon chains. Arg136 at the bottom of the substrate pocket is positioned to bind the distal halogen group of extended di-halogenated substrates. © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 24.98K | Year: 2012
This feasibility proposal seeks to evaluate the potential of marine bacteria to convert / modify complex polysaccharides derived from seaweed into non-glycaemic carbohydrates, for example, isomaltotriose, for use as sweeteners and sweetness enhancers. This project will help Aquapharm explore a range of enzymes produced from marine bacteria and explore their potential to modify a renewable source of complex carbohydrate.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 25.00K | Year: 2012
This feasibility study will investigate the potential of marine micro-organisms as a source of natural preservatives. The project will involve collaborative R&D between Aquapharm Ltd and Leatherhead Food Research Ltd. The research will combine Aquapharm’s skills in the identification of novel compounds with Leatherhead’s skills in screening for food preservation activity against a range of food spoilage microbes. Compounds identified by this approach will be subject to toxicological screening and regulatory assessment of their applicability in the market place. It is anticipated that the feasibility study will identify natural food preservatives with potential use in salt reduction programmes and “clean labels” . This will be of significant economic and health benefit to food manufacturers and consumers.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 70.89K | Year: 2012
This proposal seeks to develop a new, bio-science inspired supply chain for novel, bio-active personal care ingredients that offer performance benefits over marketed products and that can be produced cost-competitively via fermentation of marine microbes. This project will deliver natural, marine derived ingredients that meet consumers’ demands for naturally sourced, scientifically substantiated products whilst minimising potential environmental impact & offers an approach that could reduce the personal care market’s current dependence on petroleum as a source of chemicals and materials. The project will build on existing research conducted by Aquapharm (AQP) focusing on the development of novel antioxidant extracts and compounds isolated from marine microbes and enable its transition from lab to pilot scale. These extracts offer the potential to be developed as second generation functional ingredients for incorporation into personal care products.
Agency: GTR | Branch: Innovate UK | Program: | Phase: European | Award Amount: 121.50K | Year: 2012
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 225.09K | Year: 2012
This proposal seeks to evaluate the potential of marine microbial natural product extracts as sources of novel antioxidants that will lead to the development of foods/drinks with improved health benefit. . The project is a collaboration between Aquapharm, Campden BRI, The University of the Highlands and Islands and Aberdeen University.. Commercial benefits from this project include improved food preservation and superior functional health qualities. The project will assess the ability of marine extracts to up-regulate novel cytoprotective biology (Nrf2 -modulation of endogenous antioxidant systems - e.g. glutathione) combining development & commercial expertise to exploit the health potential of new 2nd generation antioxidants.